Skip to content
OpenCapital
Get started

Aprea Therapeutics, Inc. APRE Q1 2026 earnings

Reported May 13, 2026 · Before market open

Revenue$281.0K
EPS-$0.22Beat by $0.01
EPS estimate-$0.23

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$253.0K
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$281.0K
Q4 2025$3.3KIn lineQ3 2025$1.8KQ2 2025$118.1KQ1 2025$162.5KQ4 2024$205.8KMiss by $19.2K

Diluted EPS

Q1 2026-$0.22Beat by $0.01
Q4 2025-$0.32Beat by $0.06Q3 2025-$0.47Miss by $0.36Q2 2025-$0.53Beat by $0.24Q1 2025-$0.66Miss by $0.01Q4 2024-$0.49Beat by $0.20

Ask the moment Aprea Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aprea Therapeutics, Inc. report Q1 2026 earnings?
Aprea Therapeutics, Inc. (APRE) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Aprea Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Aprea Therapeutics, Inc. reported revenue of $281.0K and eps of $-0.22 for Q1 2026.
Did Aprea Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.23 by $0.01.
How did Aprea Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 73.0% from $162.5K a year earlier and eps grew 66.7% from $-0.66.
Where can I find Aprea Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-059734) and the 10-Q periodic report (0001104659-26-059743) directly on SEC EDGAR. The filing index links above go to sec.gov.